Entities / Company
sobi.
German beverage store chain
- Reports this week
- 0
- Active events
- 0
- Connections
- 12
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
Gone quiet
No new reports in 90+ days-
Apellis Pharmaceuticals secured a royalty purchase agreement with Sobi, while also awaiting FDA regulatory decisions, amid AI stock trends benefiting from tariffs.Speculative2 reports
-
Apellis Pharmaceuticals and Sobi reached a capped royalty purchase agreement following FDA approval of EMPAVELI.Some support5 reports
No events began in the chosen period. Widen it, or reset.
Around sobi this week
News at the entities that move sobi most-
Stockholm Shared contextMunters held a Capital Markets Day in Stockholm on November 11, 2026.Moves sobi
-
Colorado Shared contextDenver restricts natural gas equipment to reduce emissions.Moves sobi
-
Biogen Mentioned togetherNasdaq adjusted its index on November 11, 2026, removing Biogen and adding Seagate Technology and Western Digital.Moves sobi
Connections
The 6 strongest of 12, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Apellis Pharmaceuticals (United States) Transactional
Sobi acquired 90% of Apellis' ex-U.S. royalties, establishing a financial agreement and joint development rights.
-
European Medicines Agency Structural
EMA provides regulatory approval for Sobi's pharmaceutical products.
-
Stockholm Shared context
Sobi conducted an announcement of data while located in Stockholm.
-
American Society of Nephrology Mentioned together
Sobi presented abstracts at the American Society of Nephrology Kidney Week 2026 conference.
-
Colorado Shared context
sobi holds presentations in the state of Colorado.
-
Biogen Mentioned together
No evidence was provided describing a relationship between Biogen and sobi.
History
Events by the month they beganOctober 2026
1 eventJune 2026
3 events- Apellis is acquired by Biogen, and Aspaveli receives approval in the European Union.
- Apellis Pharmaceuticals secured a royalty purchase agreement with Sobi, while also awaiting FDA regulatory decisions, amid AI stock trends benefiting from tariffs.
- Apellis Pharmaceuticals and Sobi reached a capped royalty purchase agreement following FDA approval of EMPAVELI.